Zonix

Quick links to important sections

Zonix

Method of action: Hypnotic

Treatment option: Insomnia

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Zonix

What is Zonix? Quick Facts

Property Description
Active ingredient Zopiclone (INN)
Form Tablet (Film-coated)
Pharmacological class Sedative-Hypnotic Agent
Common use Addressing Insomnia (Sleep disorders)
Origin Synthetic (Cyclopyrrolone derivative)

What Type of Medicine is Zopiclone?

The medicine known commercially as Zonix contains the active ingredient Zopiclone, a synthetic compound classified as a Sedative-Hypnotic Agent. Chemically, it is identified as a pyrrolo[3,4-b]pyrazine derivative belonging to the Cyclopyrrolone class. This designation places Zopiclone among the non-benzodiazepine agents, often colloquially referred to as 'Z-drugs.' Zopiclone has a recognized efficacy profile as a dedicated hypnotic. Zonix is strictly available as a prescription-only medicine.

Composition and Pharmaceutical Form of Zonix

Zopiclone is formulated as a single-ingredient product, meaning its therapeutic effects are derived solely from the core compound. The product is manufactured for the oral dosage form, typically presented as a film-coated tablet. The final preparation is comprised of the Zopiclone molecule combined with necessary pharmaceutical excipients, ensuring a standardized quantity of the active compound is delivered for systemic absorption. This solid tablet format is the clinically recognized presentation for administering this class of agent.

General Purpose of this Sedative-Hypnotic Agent

The general purpose of this medication is to provide effective assistance for sleep disorders, primarily addressing various forms of insomnia. Zopiclone is classified under drugs acting on the nervous system as a hypnotic and sedative. This therapeutic intent is clinically recognized for scenarios requiring improved sleep initiation and reliable sleep maintenance. The drug's mechanism facilitates these effects by enhancing the brain's natural inhibitory pathways, thereby acting as a general Central Nervous System (CNS) depressant.

What side effects are possible with Zonix?

Possible Side Effects and Safety Information

Zonix (Zopiclone) is associated with a range of possible side effects, classified according to their frequency in official regulatory documents. These effects primarily involve the Nervous System and Psychiatric function.

Common Adverse Reactions (may affect more than 1 in 100 people) include taste alteration (often described as bitter or metallic taste), dry mouth, next-day drowsiness (somnolence), headache, and dizziness. Effects classified as Uncommon include nausea, vomiting, fatigue, and nightmares.

Serious Adverse Reactions

The official safety profile highlights the potential for rare but serious adverse reactions. These include Complex Sleep Behaviors such as sleep-driving, sleep-walking, or engaging in other activities while not fully awake, which may result in serious injury. Additionally, rare, severe allergic reactions like Angioedema (swelling of the face, tongue, or throat) and Anaphylaxis have been documented. There is also a risk of respiratory depression and the development of dependence (physical and psychological) with continued use.

Duration- and Population-Specific Safety

The risk of developing physical and psychological dependence increases with the duration of treatment, particularly when use exceeds the recommended limit. Upon cessation, a recurrence of severe insomnia (rebound insomnia) or withdrawal symptoms may occur. Safety considerations are explicitly documented for certain patient groups: Older Adults have an increased susceptibility to CNS effects, raising the risk of falls and related injuries. The medicine is contraindicated in patients with conditions such as Myasthenia gravis, severe hepatic insufficiency (liver impairment), or severe respiratory failure.

Overdose and Emergency Response

Overdose Scope

Category Official Regulatory Statements
Documented Overdose Presentations Overdose may present with a spectrum of symptoms reflecting severe Central Nervous System (CNS) depression, including somnolence, confusion, loss of balance (ataxia), and loss of muscle tone (hypotonia). Severe cases can progress to coma.
Physiological Systems Affected The official labeling notes potential compromise to the Respiratory System (respiratory depression) and the Cardiovascular System (low blood pressure).
Dose-related or Exposure-related Factors The risk of severe and fatal outcomes is substantially increased when Zonix is co-ingested with alcohol or other CNS depressants, notably opioids.
Population-specific Overdose Notes Increased risk of severe overdose is noted in elderly patients and those with existing respiratory or hepatic disorders. Caution is advised to limit the quantity prescribed to patients with depression to mitigate risk of intentional overdosage.
Emergency-response statements Immediate medical attention is required upon suspected overdose. Management should prioritize general symptomatic and supportive measures, including maintaining a clear airway and monitoring cardiac and vital signs until stability is achieved. Flumazenil is stated as an agent that may be useful.
When immediate medical help is required Urgent help must be sought if signs of severe respiratory depression or profound unresponsiveness (coma) occur.

Connection to the Overall Overdose Profile

The regulatory profile defines overdose severity based on the progression of CNS depression, especially when complicated by co-ingestion. This potential for life-threatening effects, such as respiratory compromise, mandates the explicit regulatory requirement to seek immediate medical attention and begin supportive measures.

Therapeutic Uses of Zonix

What Zonix Treats: Main Uses and Benefits

Zonix (Zopiclone) is primarily utilized for the short-term treatment of insomnia in adults. The medication is commonly used to help manage the core symptomatic cluster of insomnia and is relevant for easing difficulty falling asleep (sleep initiation) and frequent, disruptive nocturnal awakenings (sleep maintenance). This therapeutic support is generally centered on providing relief that helps ease these challenging symptoms, and may assist in the ability to achieve and sustain rest.

Therapeutic uses are relevant for managing severe insomnia, transient insomnia, and short-term insomnia. Zonix is commonly used in clinical settings where patients experience sleep disruption causing significant emotional distress or significantly interfering with functional stability, offering symptomatic assistance to cope more steadily with difficult acute phases. Support in managing proper rest may contribute to the relief of resulting daytime symptoms, such as fatigue and reduced capacity for concentration.

Quick Fact: Relief for Sleep Disruption

This medicine assists with maintaining functional stability by contributing to improved day-to-day comfort during symptomatic periods of sleep loss.

Eligibility and Restrictions for Use

Eligibility Scope

Category Regulatory Statement
Populations for whom use is allowed Adults (18 years and older) are the only approved age group.
Populations for whom use is not recommended Individuals who are pregnant or breastfeeding.
Populations for whom use is contraindicated Patients with known hypersensitivity to zopiclone; Myasthenia Gravis; severe hepatic insufficiency; severe sleep apnoea syndrome; and severe impairment of respiratory function [1.1, 1.4].
Age-related eligibility rules Use is contraindicated in children and adolescents less than 18 years, as safety and efficacy have not been established [1.1, 1.4].

Condition-Specific Eligibility and Restrictions

Category Regulatory Statement
Condition-specific eligibility rules Severe Hepatic Insufficiency and Severe Respiratory Impairment are formal contraindications [1.1].
Pregnancy and lactation eligibility Use is not recommended during pregnancy, and should generally be avoided during lactation [1.2, 3.3].
Eligibility-related restrictions Patients with a history of complex sleep behaviors (e.g., sleep-driving) after taking zopiclone are formally contraindicated [1.1, 2.3].
Conditional use populations Elderly patients (65+) and those with non-severe renal or hepatic impairment require a lower initial dose as a condition of use [1.3, 2.2].

Connection to the overall eligibility profile

Regulatory documents define who can and cannot use the medicine by establishing clear criteria based on age, pre-existing severe medical conditions which constitute contraindications, and organ function status that necessitates conditional use. These rules ensure that only the standard adult population without specified exclusion conditions is eligible for the medicine under standard labeled conditions, while formal prohibitions apply to populations where the risk is considered unacceptable.

What should I know about interactions with other medicines?

Zonix Interactions with other medicines and products

This section summarizes the officially documented interactions for Zonix (Zopiclone) based on regulatory information.

Official Interaction Statements

Classification Constraint or Mechanism (Official Statement)
Pharmacodynamic Reinforcement Co-administration with Alcohol (Ethanol) is not recommended and results in enhancement of the sedative effect and central depressive effects.
Clinically Significant Risk Concomitant use with Opioids or other narcotic analgesics may lead to increased risks of profound sedation, respiratory depression, coma, and death.
Pharmacokinetic Modification CYP3A4 Inhibitors (e.g., Erythromycin, Ketoconazole) increase Zopiclone's plasma concentrations and exposure (AUC) by impairing its clearance.
Pharmacokinetic Modification CYP3A4 Inducers (e.g., Rifampicin, St. John's Wort) decrease Zopiclone's plasma concentrations and may reduce its effect.
Timing-Based Restriction The risk of psychomotor impairment is increased if Zopiclone is taken within 12 hours of performing activities requiring complete mental alertness.

Interaction-Related Restrictions and Considerations

The product's use is contraindicated in conditions that heighten interaction-related risks, such as Severe Hepatic Insufficiency, Severe Respiratory Failure, and Myasthenia Gravis. The additive effect on the Central Nervous System is officially documented for all CNS Depressants, including sedative antihistamines, anxiolytics, and antipsychotic agents.

Mechanism of Action

Zonix modulates the canonical Wnt signaling pathway, a foundational regulator of osteoblast differentiation from mesenchymal stem cells. The primary mechanism involves the inhibition of Glycogen Synthase Kinase-3 beta (GSK-3beta) enzyme activity. Inhibition of GSK-3beta prevents the phosphorylation of beta-catenin, leading to its stabilization and accumulation within the cytosol. The stabilized beta-catenin subsequently translocates to the cell nucleus, where it acts as a transcriptional co-activator. This nuclear activity drives the expression of target genes critical for bone formation, including the production of Osteoprotegerin (OPG) and various bone morphogenetic proteins (BMPs). The resulting shift in the OPG-to-RANKL ratio favors bone formation by mediating a decrease in osteoclast progenitor differentiation and activity, thereby modulating the physiological balance between bone resorption and formation.

Dosage and Administration Information

Zonix (Zopiclone) is intended for oral administration and is available in tablet strengths of 3.75 mg and 7.5 mg. The established standard dose for an adult is 7.5 mg, which also represents the maximum single daily intake that should not be exceeded.

The dosing schedule involves a single administration per 24 hours, which must occur immediately before bedtime. This timing ensures the user has a full 7 to 8 hours available for sleep after intake. The tablet must be swallowed whole with water, without being crushed or chewed. If a dose is missed or sleep is interrupted, the dose must not be re-administered during the same night.

Specific dose adjustments apply for certain patient groups. Older adults, along with patients presenting with hepatic (liver) or renal (kidney) impairment, are typically initiated on a lower starting dose of 3.75 mg. Treatment duration is restricted and must be kept as short as possible, not exceeding four consecutive weeks, including any period of gradual dose reduction. Continued use beyond the four-week limit requires a formal re-evaluation of the patient's clinical status.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Zonix

This overview describes the research that has been conducted on Zopiclone (Zonix), outlining the types of studies available and what they have examined, without providing any clinical or medical guidance.


Evidence for Use in Short-Term Insomnia

The core evidence for Zopiclone was established through numerous short-term Randomized Controlled Trials (RCTs). These studies were used in research exploring how symptoms change over time by comparing the drug's effects against a placebo in adults experiencing various forms of insomnia. Studies monitored outcomes related to functional imbalance, primarily focusing on two key measures: the time it took participants to fall asleep (sleep latency) and how much time they spent awake after first falling asleep (Wake After Sleep Onset, WASO).

Studies monitored outcomes, and findings described patterns observed in these sleep metrics. When compared to the placebo group, studies reported measurements of Sleep Latency and WASO that varied between groups in the observed populations. This evidence provides insight into short-term changes concerning episodic or acute changes in sleep patterns.


Evidence in Insomnia Associated with Other Medical Conditions

Zopiclone was studied in specialized research contexts involving conditions presenting with cycles of stability and flare-ups, such as when insomnia is associated with other health conditions. Research explored short-term symptom changes in these specific cohorts, often using patient-reported outcomes describing perceived discomfort and overall quality of life scores as the main measures.

Data for these groups remain insufficient, as trials typically involve modest sample sizes and the observation periods are often extremely short-term, sometimes lasting only a few nights. This limited research provides context but not individual predictions for the management of conditions marked by functional limitations over an extended period.


Long-Term Studies and Follow-up Duration

The evidence highlights what is known and what is still uncertain regarding the duration of Zopiclone use. The follow-up durations were limited across the majority of the clinical trials, with the most robust data covering a period of four to six weeks.

There is limited information for long-term outcomes beyond this period, and long-term effects are not fully established. This limitation highlights what is known—and what is still uncertain. Long-term effects are not fully established when Zopiclone is used for continuous, long-term periods (e.g., several months or longer).


Summary of Research Gaps and Uncertainties

Research contributes to the broader evidence landscape, but some areas of study still contain significant uncertainties. Key research limitation frames include the fact that the follow-up durations were limited in most regulatory studies. Furthermore, evidence quality varies across studies, and data for certain groups remain insufficient, meaning subgroup findings are uncertain. Studies help show what has been observed so far in group patterns, but research does not determine whether an individual will respond similarly.

Frequently Asked Questions (FAQ)

Common questions about Zonix (FAQ)

Q: Is Zonix the same type of medicine as [similar generic drug name]?

Zonix contains the active ingredient zopiclone, which is classified by health authorities as a sedative-hypnotic agent. It belongs to the Cyclopyrrolone chemical class and is one of the medications often referred to as 'Z-drugs,' a term that distinguishes it from benzodiazepines.


Q: Do I need to avoid any specific foods or drinks while using Zonix?

Official regulatory documentation states that the medicine's absorption is not affected by food. However, co-administration with alcohol is not recommended in official documentation because alcohol can significantly enhance the sedative effects and central depressive effects of the medicine.


Q: Is Zonix safe for older people, like those over 65?

The conditional use of Zonix for older adults is addressed in official documents through a lower recommended starting dose. This population is also acknowledged to have increased sensitivity to central nervous system effects, which can increase the risk of falls and related injuries.


Q: Does Zonix have any long-term side effects that regulatory bodies monitor?

Regulatory authorities track safety information through post-marketing surveillance programs. Specifically, they monitor for the potential for complex sleep behaviors that may result in serious injury, as well as the risks of physical and psychological dependence and withdrawal symptoms.


Q: How does Zonix differ from other treatments for the same condition?

Zonix is a synthetic compound categorized as a sedative-hypnotic agent in the Cyclopyrrolone chemical class. This official pharmacological classification separates it from other medications used for sleep disorders, such as the benzodiazepine class.


Q: Does Zonix interact with common cold or allergy medicines?

The official documentation notes that Zonix may have an additive effect when combined with any drug classified as a Central Nervous System (CNS) depressant. This may include certain sedative antihistamines found in some cold and allergy medicines, because of the documented additive effect on the Central Nervous System.


Q: What is the evidence level (e.g., phase 3 trials) for Zonix?

The evidence base for Zonix was established primarily through numerous short-term Randomized Controlled Trials (RCTs). These studies were used in research to examine changes in key sleep metrics, such as the time taken to fall asleep (sleep latency) and the time spent awake after first falling asleep (WASO).


Q: Is Zonix generally well-tolerated?

The official product information classifies adverse reactions by how often they occur. Common reactions, those affecting more than 1 in 100 people, include taste alteration (metallic or bitter taste), dry mouth, next-day drowsiness, headache, and dizziness.


Q: Can Zonix affect my mood or emotional state?

Official documents list various side effects related to mood and psychiatric function. These include reports of anxiety, agitation, irritability, and a depressed mood (feeling low or sad).


Q: Are there any known interactions with herbal supplements and Zonix?

Yes, official documentation reports interactions with certain herbal supplements. Specifically, supplements that act as CYP3A4 enzyme inducers, such as St. John's Wort, can decrease the concentration of zopiclone in the body. This decrease in concentration is documented as possibly reducing the medicine's effect.


Q: What is the expected long-term effect of Zonix on the body?

Regulatory documents restrict the duration of use to a maximum of four consecutive weeks, including any period of gradual dose reduction. Long-term effects beyond this short period are not fully established, and the risk of physical and psychological dependence increases with treatment duration.


Q: Does Zonix cause weight gain or weight loss?

Official regulatory documentation, which lists the known common, uncommon, and rare side effects, does not include weight gain or weight loss among the documented adverse reactions for Zonix.


Q: How long does it usually take to notice Zonix working?

Official documentation states that the active ingredient, zopiclone, is rapidly absorbed following administration. Peak concentrations in the body are typically reached within 1.5 to 2 hours after the dose is taken.


Q: Can Zonix be taken safely with pain relievers like ibuprofen?

Official sources do not specifically list non-opioid pain relievers like ibuprofen as an explicitly known interacting drug. However, official guidance highlights the need to consider the potential for additive effects on the central nervous system when taking any medicine.


Q: Is Zonix a controlled substance?

Yes, Zonix (zopiclone) is classified as a controlled substance by regulatory bodies in several countries. For instance, the US Drug Enforcement Administration (DEA) classifies it as a Schedule IV controlled substance due to its potential for abuse and dependence.


Q: How long does Zonix stay in your system after stopping it?

Pharmacokinetic data from official documents indicate that the elimination half-life of unchanged zopiclone is approximately 5 hours in adults. This means the concentration of the substance is substantially cleared from the body relatively quickly.


Q: Does Zonix require regular blood tests while being used?

Regulatory information does not explicitly mandate regular blood tests for all users during treatment. However, Official guidance notes that the use of Zonix may be conditioned by dose adjustments for patients with pre-existing severe liver or kidney impairment.


Q: Do health authorities track new information about Zonix safety?

Yes, health authorities, including the World Health Organization (WHO) and the US Food and Drug Administration (FDA), maintain robust post-marketing surveillance programs. These programs are designed to track and report new information about the safety profile and long-term effects of medications.


Q: Can Zonix be taken by someone with a history of heart problems?

While a history of heart problems is not listed as a formal contraindication in official documents, the medicine is strictly prohibited in patients with severe respiratory failure. Official guidance indicates that such conditions necessitate assessment.


Q: What if I take too much Zonix?

Overdose is officially described as a medical emergency. Symptoms of an overdose may include prolonged sleep, confusion, profound sedation, shallow breathing (respiratory depression), and low blood pressure (hypotension).


Q: Why do some people say Zonix makes them feel jittery?

Official adverse reaction documents list agitation as an uncommon side effect of Zonix. Additionally, other reported psychiatric effects include nervousness, confusion, and abnormal thinking.


Q: Does Zonix affect blood pressure?

Low blood pressure, or hypotension, is not listed as a common or uncommon side effect at standard doses. However, official documentation regarding overdose symptoms notes that low blood pressure is a potential result of taking too much of the medicine.


Q: How does the FDA classify the safety of Zonix?

The US Drug Enforcement Administration (DEA) classifies Zonix's active ingredient as a Schedule IV controlled substance. Furthermore, the FDA has issued a Boxed Warning that highlights the risk of serious injuries caused by complex sleep behaviors while using the medicine.

How should Zonix be stored and disposed of?

How to Store and Dispose of Zonix (Zopiclone)

Zonix must be stored under specific conditions to maintain the stability of the tablet. Storage temperatures must not exceed 30 C. The medicine must be protected from light and moisture, meaning the blister card must be kept inside the original outer carton until use.

Handling and Safety

It is mandatory to store Zonix out of the sight and out of the reach of children. The medicine should not be used after the expiry date.

Disposal

To protect the environment, the tablets must not be thrown away in household waste or wastewater. Unused or expired medication should be taken to a pharmacist who can provide guidance on appropriate disposal methods.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Zonix found in:

A-Z Index: